70 results
Page 3 of 4
8-K
EX-99.1
6im 7twgl6l7jmk
16 May 22
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
4:24pm
8-K
EX-99.1
mb38ao3i9t64tfyh yo1
21 Mar 22
Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201
4:11pm
424B5
byoyffkvbp3d rmpp
17 Mar 22
Prospectus supplement for primary offering
4:02pm
S-3
d3nl006 yij2fd058
8 Mar 22
Shelf registration
4:34pm
8-K
EX-99.1
wumng wbs2
3 Mar 22
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:36pm
8-K
EX-99.1
fwqljagevrtq64 8o
15 Nov 21
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
4:21pm
8-K
EX-99.1
t69r6suuu0rhr29nhfv
9 Nov 21
Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501
4:49pm
8-K
EX-99.1
2vkuuynplsz2c tnt8
29 Sep 21
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
12:00am
8-K
EX-99.1
iqwdl
16 Aug 21
Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
4:19pm
8-K
EX-99.2
a8bsudremt
14 Jun 21
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
4:40pm
8-K
EX-99.1
cw5e8gvwiuei
14 Jun 21
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
4:40pm
10-Q
gh6jtgv6yek520l1rwt
14 May 21
Quarterly report
4:59pm
8-K
EX-99.1
zkau7qft odhl
13 May 21
Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:17pm
10-K
e4f0xjjoujqlmdsf7t
30 Mar 21
Annual report
5:21pm
8-K
EX-99.1
onz qnpaql
30 Mar 21
Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
5:04pm
424B4
rohhgo69pv8l 188d0g0
8 Feb 21
Prospectus supplement with pricing info
4:01pm